Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study

Overview

Journal Haematologica

Specialty Hematology

Date 2010 Jul 17

PMID 20634495

Citations 40

Authors

Catherine Cordonnier

Montserrat Rovira

Johan Maertens

Eduardo Olavarria

Catherine Faucher

Karin Bilger

Arnaud Pigneux

Oliver A Cornely

Andrew J Ullmann

Rodrigo Martino Bofarull

Rafael de la Camara

Maja Weisser

Effie Liakopoulou

Manuel Abecasis

Claus Peter Heussel

Marc Pineau

Per Ljungman

Hermann Einsele

Affiliations

Soon will be listed here.

Abstract

Background: Recurrence of prior invasive fungal infection (relapse rate of 30-50%) limits the success of stem cell transplantation. Secondary prophylaxis could reduce disease burden and improve survival.

Design And Methods: A prospective, open-label, multicenter trial was conducted evaluating voriconazole (4 mg/kg/12 h intravenously or 200 mg/12 h orally) as secondary antifungal prophylaxis in allogeneic stem cell transplant recipients with previous proven or probable invasive fungal infection. Voriconazole was started 48 h or more after completion of conditioning chemotherapy and was planned to be continued for 100-150 days. Patients were followed for 12 months. The primary end-point of the study was the incidence of proven or probable invasive fungal infection.

Results: Forty-five patients were enrolled, 41 of whom had acute leukemia. Previous invasive fungal infections were proven or probable aspergillosis (n=31), proven candidiasis (n=5) and other proven or probable infections (n=6); prior infection could not be confirmed in three patients. The median duration of voriconazole prophylaxis was 94 days. Eleven patients (24%) died within 12 months of transplantation, but only one due to systemic fungal disease. Three invasive fungal infections occurred post-transplant: two relapses (one candidemia and one fatal scedosporiosis) and one new zygomycosis in a patient with previous aspergillosis. The 1-year cumulative incidence of invasive fungal disease was 6.7±3.6%. Two patients were withdrawn from the study due to treatment-related adverse events (i.e. liver toxicity).

Conclusions: Voriconazole appears to be safe and effective for secondary prophylaxis of systemic fungal infection after allogeneic stem cell transplantation. The observed incidence of 6.7% (with one attributable death) is considerably lower than the relapse rate reported in historical controls, thus suggesting that voriconazole is a promising prophylactic agent in this population.

Citing Articles

Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights.

Saleh A, Schulz J, Schlender J, Aulin L, Konrad A, Kluwe F Clin Pharmacokinet. 2024; 63(11):1609-1630.

PMID: 39476315 PMC: 11573852. DOI: 10.1007/s40262-024-01434-8.

Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.

Neoh C, Chen S, Lanternier F, Tio S, Halliday C, Kidd S Clin Microbiol Rev. 2024; 37(2):e0000423.

PMID: 38551323 PMC: 11237582. DOI: 10.1128/cmr.00004-23.

Update on therapeutic approaches for invasive fungal infections in adults.

Boutin C, Luong M Ther Adv Infect Dis. 2024; 11:20499361231224980.

PMID: 38249542 PMC: 10799587. DOI: 10.1177/20499361231224980.

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.

Kluwe F, Michelet R, Huisinga W, Zeitlinger M, Mikus G, Kloft C Clin Pharmacokinet. 2023; 62(10):1461-1477.

PMID: 37603216 PMC: 10520167. DOI: 10.1007/s40262-023-01274-y.

Invasive Fusariosis in Patients with Hematologic Diseases.

Nucci M, Barreiros G, Akiti T, Anaissie E, Nouer S J Fungi (Basel). 2021; 7(10).

PMID: 34682236 PMC: 8537065. DOI: 10.3390/jof7100815.

References

Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F . Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group. Bone Marrow Transplant. 1995; 16(2):323-4. View

de Fabritiis P, Spagnoli A, Di Bartolomeo P, Locasciulli A, Cudillo L, Milone G . Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant. 2007; 40(3):245-9. DOI: 10.1038/sj.bmt.1705720. View

Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A . Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of.... Blood. 2006; 108(9):2928-36. PMC: 1895522. DOI: 10.1182/blood-2006-03-008706. View

Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706. DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o. View

Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347(6):408-15. DOI: 10.1056/NEJMoa020191. View

Kruger W, Russmann B, de Wit M, Kroger N, Renges H, Sobottka I . Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol. 2005; 113(2):104-8. DOI: 10.1159/000083447. View

Ullmann A, Lipton J, Vesole D, Chandrasekar P, Langston A, Tarantolo S . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356(4):335-47. DOI: 10.1056/NEJMoa061098. View

Martino R, Lopez R, Sureda A, Brunet S . Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Haematologica. 1997; 82(3):297-304. View

Sipsas N, Kontoyiannis D . Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006; 42(11):1584-91. DOI: 10.1086/503844. View

10.

Cornely O, Maertens J, Bresnik M, Ebrahimi R, Ullmann A, Bouza E . Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007; 44(10):1289-97. DOI: 10.1086/514341. View

11.

Cornely O . Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection. 2008; 36(4):296-313. DOI: 10.1007/s15010-008-7357-z. View

12.

Perfect J, Marr K, Walsh T, Greenberg R, Dupont B, la Torre-Cisneros J . Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36(9):1122-31. DOI: 10.1086/374557. View

13.

Cordonnier C, Maury S, Pautas C, Bastie J, Chehata S, Castaigne S . Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant. 2004; 33(9):943-8. DOI: 10.1038/sj.bmt.1704469. View

14.

Allinson K, Kolve H, Gumbinger H, Vormoor H, Ehlert K, Groll A . Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother. 2008; 61(3):734-42. DOI: 10.1093/jac/dkm521. View

15.

Espinel-Ingroff A, Johnson E, Hockey H, Troke P . Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008; 61(3):616-20. DOI: 10.1093/jac/dkm518. View

16.

Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59. DOI: 10.1056/NEJMoa061094. View

17.

Thursky K, Playford E, Seymour J, Sorrell T, Ellis D, Guy S . Recommendations for the treatment of established fungal infections. Intern Med J. 2008; 38(6b):496-520. DOI: 10.1111/j.1445-5994.2008.01725.x. View

18.

Fukuda T, Boeckh M, Guthrie K, Mattson D, Owens S, Wald A . Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant. 2004; 10(7):494-503. DOI: 10.1016/j.bbmt.2004.02.006. View

19.

Offner F, Cordonnier C, Ljungman P, Prentice H, Engelhard D, De Bacquer D . Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis. 1998; 26(5):1098-103. DOI: 10.1086/520274. View

20.

Ascioglu S, Rex J, De Pauw B, Bennett J, Bille J, Crokaert F . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2001; 34(1):7-14. DOI: 10.1086/323335. View